Combination therapy comprising a composition of mesenchymal stromal cells and hyaluronic acid for use in treatment of osteoarthritis

A combination product or a kit for treating osteoarthritis in a human subject, comprising a combination of:

• a composition comprising about 20 to 30 million mesenchymal stromal cells, about 1 ml of multiple electrolyte solution and about 1 ml of protein free, serum free, animal component free formulation of about 2.5% to 5% dimethyl sulfoxide (DMSO);
• and
• about 2 ml of mid molecular weight hyaluronic acid,
• wherein the composition is devoid of human serum albumin (HSA);
• and
• wherein the mesenchymal stromal cells are bone marrow derived pooled mesenchymal stromal cells obtained from pooling mesenchymal stromal cells from at least 3 donors.

A method of increasing levels of plasma anti-inflammatory marker interleukin-10 (IL-10) and/or decreasing levels of disease progression urinary marker crosslinked C-telopeptides of type II collagen (CTX-II) in a human subject suffering from osteoarthritis, said method comprising administering to the subject a combination of:

• a. a composition comprising about 20 to 30 million mesenchymal stromal cells, multiple electrolyte solution and protein free, serum free, animal component free formulation of dimethyl sulfoxide (DMSO);
• and
• b. mid molecular weight hyaluronic acid,
• wherein the composition is devoid of human serum albumin (HSA);
• wherein the mesenchymal stromal cells are bone marrow derived pooled mesenchymal stromal cells obtained from pooling mesenchymal stromal cells from at least 3 donors;
• and
• wherein when the combination is administered to the subject, the levels are increased and/or decreased in relation to the subject prior to administration of the said combination.